Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
13 janv. 2025 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million ––...
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on...
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
26 nov. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI...
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
12 nov. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London...
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
29 oct. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life...
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
28 oct. 2024 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals...
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
22 oct. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024...
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
01 oct. 2024 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, has teamed up with National Hockey...
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
28 août 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo...
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
23 juil. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $405 - $415 million...